Filing Details

Accession Number:
0001209191-21-026747
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-14 20:19:04
Reporting Period:
2021-04-12
Accepted Time:
2021-04-14 20:19:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733294 Generation Bio Co. GBIO Pharmaceutical Preparations (2834) 814301281
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742765 Atlas Venture Associates X, Llc 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
1742766 Atlas Venture Associates X, L.p. 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-04-12 63,353 $26.07 77,329 No 4 S Direct
Common Stock Disposition 2021-04-12 10,771 $26.61 66,558 No 4 S Direct
Common Stock Disposition 2021-04-13 35,791 $25.09 30,767 No 4 S Direct
Common Stock Disposition 2021-04-13 7,354 $25.53 23,413 No 4 S Direct
Common Stock Disposition 2021-04-14 10,539 $26.40 12,874 No 4 S Direct
Common Stock Disposition 2021-04-14 12,874 $26.78 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,111,939 Indirect See footnote
Footnotes
  1. Shares were sold pursuant to a Rule 10b5-1 trading plan dated January 14, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.405 to $26.40 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (8).
  3. The shares are held directly by Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.20 inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.37 to $25.36 inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.37 to $26.04 inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.58 to $26.57 inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.58 to $27.14 inclusive.
  9. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is AVA X LP and the general partner of AVA X LP is AVA X LLC. Each of AVA X LP and AVA LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of its respective pecuniary interest therein, if any.